ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA Methylation.

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Metastatic cancer presents significant clinical challenges due to poorly understood mechanisms and limited therapies.
• N6-methyladenosine (m6A) RNA modification is frequently dysregulated in cancer, and its regulators are potential therapeutic targets.
• Understanding m6A's role in metastasis is crucial for developing novel treatment strategies.

Purpose of the Study:

• To investigate the role of m6A writer complex components in metastatic progression.
• To identify specific molecular mechanisms by which m6A alterations drive cancer metastasis.
• To evaluate the therapeutic potential of targeting m6A regulators in metastatic cancer.

Main Methods:

• Analysis of ZC3H13 expression in patient cohorts, particularly in metastatic prostate cancer.
• In vitro and in vivo functional assays to assess the impact of ZC3H13 loss on cell migration and invasion.
• Examination of m6A methylation levels and target mRNA stability following ZC3H13 manipulation.
• Treatment of ZC3H13-deficient cells with FDA-approved m6A demethylase inhibitors.

Main Results:

• Loss of ZC3H13, often co-occurring with RB1 and BRCA2 loss in metastatic prostate cancer, was identified as a key regulator of metastasis.
• ZC3H13 deficiency altered m6A writer complex activity, leading to reduced global m6A methylation.
• This reduction increased the stability of transcripts promoting cell migration and invasion.
• FDA-approved m6A demethylase inhibitors effectively suppressed the metastatic capabilities of ZC3H13-deficient cells.

Conclusions:

• ZC3H13 loss contributes to cancer metastasis through altered m6A methylation patterns and subsequent changes in mRNA stability.
• The findings elucidate the selective mRNA methylation mechanisms of the m6A writer complex and the pathological impact of its altered composition.
• Targeting m6A demethylases presents a promising therapeutic strategy for patients with metastatic cancers characterized by ZC3H13 deficiency.